1
|
Tadié JM, Locher C, Maamar A, Reignier J, Asfar P, Commereuc M, Lesouhaitier M, Gregoire M, Le Pabic E, Bendavid C, Moreau C, Diehl JL, Gey A, Tartour E, Le Tulzo Y, Thibault R, Terzi N, Gacouin A, Roussel M, Delclaux C, Tarte K, Cynober L. Enteral citrulline supplementation versus placebo on SOFA score on day 7 in mechanically ventilated critically ill patients: the IMMUNOCITRE randomized clinical trial. Crit Care 2023; 27:381. [PMID: 37784110 PMCID: PMC10546668 DOI: 10.1186/s13054-023-04651-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 09/18/2023] [Indexed: 10/04/2023] Open
Abstract
BACKGROUND Restoring plasma arginine levels through enteral administration of L-citrulline in critically ill patients may improve outcomes. We aimed to evaluate whether enteral L-citrulline administration reduced organ dysfunction based on the Sequential Organ Failure Assessment (SOFA) score and affected selected immune parameters in mechanically ventilated medical intensive care unit (ICU) patients. METHODS A randomized, double-blind, multicenter clinical trial of enteral administration of L-citrulline versus placebo for critically ill adult patients under invasive mechanical ventilation without sepsis or septic shock was conducted in four ICUs in France between September 2016 and February 2019. Patients were randomly assigned to receive enteral L-citrulline (5 g) every 12 h for 5 days or isonitrogenous, isocaloric placebo. The primary outcome was the SOFA score on day 7. Secondary outcomes included SOFA score improvement (defined as a decrease in total SOFA score by 2 points or more between day 1 and day 7), secondary infection acquisition, ICU length of stay, plasma amino acid levels, and immune biomarkers on day 3 and day 7 (HLA-DR expression on monocytes and interleukin-6). RESULTS Of 120 randomized patients (mean age, 60 ± 17 years; 44 [36.7%] women; ICU stay 10 days [IQR, 7-16]; incidence of secondary infections 25 patients (20.8%)), 60 were allocated to L-citrulline and 60 were allocated to placebo. Overall, there was no significant difference in organ dysfunction as assessed by the SOFA score on day 7 after enrollment (4 [IQR, 2-6] in the L-citrulline group vs. 4 [IQR, 2-7] in the placebo group; Mann‒Whitney U test, p = 0.9). Plasma arginine was significantly increased on day 3 in the treatment group, while immune parameters remained unaffected. CONCLUSION Among mechanically ventilated ICU patients without sepsis or septic shock, enteral L-citrulline administration did not result in a significant difference in SOFA score on day 7 compared to placebo. TRIAL REGISTRATION ClinicalTrials.gov Identifier NCT02864017 (date of registration: 11 August 2016).
Collapse
Affiliation(s)
- Jean-Marc Tadié
- UMR 1236, Univ Rennes, INSERM, Établissement Français du Sang, LabexIGO, Rennes, France.
- SITI Laboratory, CHU Rennes, Rennes, France.
- Réanimation Médicale, CHU Rennes, Rennes, France.
- Centre d'investigation clinique de Rennes (CIC1414), CHU Rennes, Rennes, France.
- Centre Hospitalier Universitaire, Université de Rennes 1, Rennes, France.
- Hôpital Pontchaillou, CHU Rennes, 2 rue Henri Le Guillloux, 35033, Rennes Cedex, France.
| | - Clara Locher
- Inserm, Centre d'investigation clinique de Rennes (CIC1414), service de pharmacologie clinique, Institut de recherche en santé, environnement et travail (Irset), UMR S 1085, EHESP, Univ Rennes, CHU Rennes, 35000, Rennes, France
| | - Adel Maamar
- UMR 1236, Univ Rennes, INSERM, Établissement Français du Sang, LabexIGO, Rennes, France
| | - Jean Reignier
- MIP, UR 4334, Médecine Intensive Réanimation, Nantes Université, CHU Nantes, 44000, Nantes, France
| | - Pierre Asfar
- Département de Médecine Intensive - Réanimation et Médecine Hyperbare, Centre Hospitalier Universitaire, Angers, France
| | - Morgane Commereuc
- Service de Réanimation Médicale, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Paris, France
| | - Mathieu Lesouhaitier
- UMR 1236, Univ Rennes, INSERM, Établissement Français du Sang, LabexIGO, Rennes, France
- SITI Laboratory, CHU Rennes, Rennes, France
- Réanimation Médicale, CHU Rennes, Rennes, France
- Centre d'investigation clinique de Rennes (CIC1414), CHU Rennes, Rennes, France
| | - Murielle Gregoire
- UMR 1236, Univ Rennes, INSERM, Établissement Français du Sang, LabexIGO, Rennes, France
- SITI Laboratory, CHU Rennes, Rennes, France
| | - Estelle Le Pabic
- Inserm, Centre d'investigation clinique de Rennes (CIC1414), service de pharmacologie clinique, Institut de recherche en santé, environnement et travail (Irset), UMR S 1085, EHESP, Univ Rennes, CHU Rennes, 35000, Rennes, France
| | - Claude Bendavid
- Laboratoire de Biochimie-Métabolique, CHU Rennes, Rennes, France
| | - Caroline Moreau
- Laboratoire de Biochimie-Métabolique, CHU Rennes, Rennes, France
| | - Jean-Luc Diehl
- Service de Réanimation Médicale, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Paris, France
| | - Alain Gey
- INSERM U970, Université Paris Cité, Paris, France
- Hôpital européen Georges Pompidou, Service d'Immunologie biologique, 20, Rue Leblanc, 75015, Paris, France
| | - Eric Tartour
- INSERM U970, Université Paris Cité, Paris, France
- Hôpital européen Georges Pompidou, Service d'Immunologie biologique, 20, Rue Leblanc, 75015, Paris, France
| | - Yves Le Tulzo
- UMR 1236, Univ Rennes, INSERM, Établissement Français du Sang, LabexIGO, Rennes, France
- SITI Laboratory, CHU Rennes, Rennes, France
- Réanimation Médicale, CHU Rennes, Rennes, France
| | - Ronan Thibault
- INSERM, INRAE, Nutrition Métabolismes et Cancer, NuMeCan, Univ Rennes, CHU Rennes, Service d'endocrinologie-Diabétologie-Nutrition, Rennes, France
| | - Nicolas Terzi
- UMR 1236, Univ Rennes, INSERM, Établissement Français du Sang, LabexIGO, Rennes, France
| | - Arnaud Gacouin
- UMR 1236, Univ Rennes, INSERM, Établissement Français du Sang, LabexIGO, Rennes, France
| | - Mikael Roussel
- UMR 1236, Univ Rennes, INSERM, Établissement Français du Sang, LabexIGO, Rennes, France
- SITI Laboratory, CHU Rennes, Rennes, France
| | - Christophe Delclaux
- AP-HP, Hôpital Robert Debré, Service de Physiologie Pédiatrique -Centre du Sommeil - CRMR Hypoventilations alvéolaires rares, INSERM NeuroDiderot, Université de Paris, 75019, Paris, France
| | - Karin Tarte
- UMR 1236, Univ Rennes, INSERM, Établissement Français du Sang, LabexIGO, Rennes, France
- SITI Laboratory, CHU Rennes, Rennes, France
| | - Luc Cynober
- Faculty of Pharmacy, Paris Cité University, Paris, France
| |
Collapse
|
2
|
Darreau C, Martino F, Saint-Martin M, Jacquier S, Hamel JF, Nay MA, Terzi N, Ledoux G, Roche-Campo F, Camous L, Pene F, Balzer T, Bagate F, Lorber J, Bouju P, Marois C, Robert R, Gaudry S, Commereuc M, Debarre M, Chudeau N, Labroca P, Merouani K, Egreteau PY, Peigne V, Bornstain C, Lebas E, Benezit F, Vally S, Lasocki S, Robert A, Delbove A, Lerolle N. Use, timing and factors associated with tracheal intubation in septic shock: a prospective multicentric observational study. Ann Intensive Care 2020; 10:62. [PMID: 32449053 PMCID: PMC7245631 DOI: 10.1186/s13613-020-00668-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Accepted: 04/22/2020] [Indexed: 01/20/2023] Open
Abstract
Background No recommendation exists about the timing and setting for tracheal intubation and mechanical ventilation in septic shock. Patients and methods This prospective multicenter observational study was conducted in 30 ICUs in France and Spain. All consecutive patients presenting with septic shock were eligible. The use of tracheal intubation was described across the participating ICUs. A multivariate analysis was performed to identify parameters associated with early intubation (before H8 following vasopressor onset). Results Eight hundred and fifty-nine patients were enrolled. Two hundred and nine patients were intubated early (24%, range 4.5–47%), across the 18 centers with at least 20 patients included. The cumulative intubation rate during the ICU stay was 324/859 (38%, range 14–65%). In the multivariate analysis, seven parameters were significantly associated with early intubation and ranked as follows by decreasing weight: Glasgow score, center effect, use of accessory respiratory muscles, lactate level, vasopressor dose, pH and inability to clear tracheal secretions. Global R-square of the model was only 60% indicating that 40% of the variability of the intubation process was related to other parameters than those entered in this analysis. Conclusion Neurological, respiratory and hemodynamic parameters only partially explained the use of tracheal intubation in septic shock patients. Center effect was important. Finally, a vast part of the variability of intubation remained unexplained by patient characteristics. Trial registration Clinical trials NCT02780466, registered on May 23, 2016. https://clinicaltrials.gov/ct2/show/NCT02780466?term=intubatic&draw=2&rank=1.
Collapse
Affiliation(s)
- C Darreau
- Medical and Surgical Intensive Care Unit, Le Mans Hospital, Le Mans, France
| | - F Martino
- Medical and Surgical Intensive Care Unit, Guadeloupe University Hospital, Les Abymes, Guadeloupe, France
| | - M Saint-Martin
- Medical and Surgical Intensive Care Unit, Le Mans Hospital, Le Mans, France
| | - S Jacquier
- Medical Intensive Care Unit, Tours University Hospital, Tours, France
| | - J F Hamel
- Methodology and Statistics Department, Angers University Hospital, Angers, France
| | - M A Nay
- Medical Intensive Care Unit, Orleans Regional Hospital, Orléans, France
| | - N Terzi
- Medical Intensive Care Unit, Grenoble University Hospital, La Tronche, France
| | - G Ledoux
- Medical and Surgical Intensive Care Unit, Lille University Hospital, Lille, France
| | - F Roche-Campo
- Intensive Care Unit, Hospital Verge de la Cinta, Tortosa, Spain
| | - L Camous
- Medical Intensive Care Unit, Bicêtre Hospital, AP-HP, Paris, France
| | - F Pene
- Medical Intensive Care Unit, Cochin Hospital, AP-HP, Paris, France
| | - T Balzer
- Medical Intensive Care Unit, Brest University Hospital, Brest, France
| | - F Bagate
- Medical Intensive Care Unit, Henri Mondor Hospital, AP-HP, Paris, France
| | - J Lorber
- Medical and Surgical Intensive Care Unit, La-Roche-sur-Yon Hospital, La Roche-sur-Yon, France
| | - P Bouju
- Medical and Surgical Intensive Care Unit, Sud Bretagne Hospital, Lorient, France
| | - C Marois
- Medical Intensive Care Unit, Pitié-Salpétrière Hospital, AP-HP, Paris, France
| | - R Robert
- Medical Intensive Care Unit, Poitiers University Hospital, Poitiers, France
| | - S Gaudry
- Medical Intensive Care Unit, Louis Mourier Hospital, AP-HP, Colombes, France
| | - M Commereuc
- Medical Intensive Care Unit, Georges Pompidou European Hospital, AP-HP, Paris, France
| | - M Debarre
- Medical and Surgical Intensive Care Unit, Saint Brieuc Hospital, Saint Brieuc, France
| | - N Chudeau
- Medical and Surgical Intensive Care Unit, Le Mans Hospital, Le Mans, France
| | - P Labroca
- Medical Intensive Care Unit, Nancy University Central Hospital, Nancy, France
| | - K Merouani
- Medical and Surgical Intensive Care Unit, Alençon Hospital, Alençon, France
| | - P Y Egreteau
- Medical and Surgical Intensive Care Unit, Morlaix Hospital, Morlaix, France
| | - V Peigne
- Medical and Surgical Intensive Care Unit, Métropole Savoie Hospital, Chambéry, France
| | - C Bornstain
- Medical Intensive Care Unit, Le Raincy-Montfermeil Hospital, Montfermeil, France
| | - E Lebas
- Medical and Surgical Intensive Care Unit, Bretagne Atlantique Hospital, Vannes, France
| | - F Benezit
- Medical and Surgical Intensive Care Unit, Rennes University Hospital, Rennes, France
| | - S Vally
- Medical and Surgical Intensive Care Unit, Martinique University Hospital, Fort-de-France, Martinique, France
| | - S Lasocki
- Surgical Intensive Care Unit, Angers University Hospital, Angers, France
| | - A Robert
- Medical Intensive Care Unit, Nice University Hospital, Nice, France
| | - A Delbove
- Medical Intensive Care Unit, Nantes University Hospital, Nantes, France
| | - N Lerolle
- Medical Intensive Care Unit, Angers University Hospital, Angers, France.
| |
Collapse
|
3
|
Commereuc M, Nevoret C, Radermacher P, Katsahian S, Asfar P, Schortgen F. Hyperchloremia is not associated with AKI or death in septic shock patients: results of a post hoc analysis of the "HYPER2S" trial. Ann Intensive Care 2019; 9:95. [PMID: 31440853 PMCID: PMC6706496 DOI: 10.1186/s13613-019-0570-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Accepted: 08/13/2019] [Indexed: 02/06/2023] Open
Abstract
Background Recent data suggest that hyperchloremia induced by fluid resuscitation is associated with acute kidney injury (AKI) and mortality, particularly in sepsis. Experimental studies showed that hyperchloremia could affect organ functions. In patients with septic shock, we examined the relationship between serum chloride concentration and both renal function and survival. Methods Post hoc analysis of the “HYPER2S” trial database (NCT01722422) including 434 patients with septic shock randomly assigned for resuscitation with 0.9% or 3% saline. Metabolic parameters were recorded up to 72 h. Metabolic effects of hyperchloremia (> 110 mmol/L) were studied stratified for hyperlactatemia (> 2 mmol/L). Cox models were constructed to assess the association between chloride parameters, day-28 mortality and AKI. Results 413 patients were analysed. The presence of hyperlactatemia was significantly more frequent than hyperchloremia (62% versus 71% of patients, respectively, p = 0.006). Metabolic acidosis was significantly more frequent in patients with hyperchloremia, no matter the presence of hyperlactatemia, p < 0.001. Adjusted risk of AKI and mortality were not significantly associated with serum chloride, hyperchloremia, maximal chloremia and delta chloremia (maximal-H0 [Cl]). Conclusions Despite more frequent metabolic acidosis, hyperchloremia was not associated with an increased risk for AKI or mortality. Trial registration ClinicalTrials.gov, identifier: NCT01722422, registered 2 November 2012
Collapse
Affiliation(s)
- Morgane Commereuc
- Service de Réanimation et Surveillance Continue Adulte, Centre hospitalier intercommunal de Créteil, 94000, Créteil, France
| | - Camille Nevoret
- INSERM, UMR_S 1138, Université Paris Descartes, Sorbonne Universités, UPMC Université Paris 06, Centre de Recherche des Cordeliers, Paris, France.,Unité d'Épidémiologie et de Recherche Clinique, Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.,INSERM, Centre d'Investigation Clinique 1418, Module Épidémiologie Clinique, Paris, France
| | - Peter Radermacher
- Institut für Anästhesiologische Pathophysiologie und Verfahrensentwicklung, Universitätsklinikum Ulm, Helmholtzstr 8-1, 89081, Ulm, Germany
| | - Sandrine Katsahian
- INSERM, UMR_S 1138, Université Paris Descartes, Sorbonne Universités, UPMC Université Paris 06, Centre de Recherche des Cordeliers, Paris, France.,Unité d'Épidémiologie et de Recherche Clinique, Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.,INSERM, Centre d'Investigation Clinique 1418, Module Épidémiologie Clinique, Paris, France
| | - Pierre Asfar
- Département de Médecine Intensive-Réanimation et Médecine Hyperbare, CHU d'Angers, Angers, France
| | - Frédérique Schortgen
- Service de Réanimation et Surveillance Continue Adulte, Centre hospitalier intercommunal de Créteil, 94000, Créteil, France. .,INSERM U955 Equipe 13, Faculté de Médecine, 94010, Créteil, France.
| | | |
Collapse
|
4
|
Commereuc M, Schortgen F. Néphrotoxicité des produits de remplissage. Nephrol Ther 2018; 14:555-563. [DOI: 10.1016/j.nephro.2018.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
5
|
Bataille A, Galichon P, Chelghoum N, Oumoussa BM, Ziliotis MJ, Sadia I, Vandermeersch S, Simon-Tillaux N, Legouis D, Cohen R, Xu-Dubois YC, Commereuc M, Rondeau E, Le Crom S, Hertig A. Increased Fatty Acid Oxidation in Differentiated Proximal Tubular Cells Surviving a Reversible Episode of Acute Kidney Injury. Cell Physiol Biochem 2018; 47:1338-1351. [PMID: 29929186 DOI: 10.1159/000490819] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Accepted: 11/19/2017] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND/AIMS Fatty acid oxidation (FAO), the main source of energy produced by tubular epithelial cells in the kidney, was found to be defective in tubulo-interstitial samples dissected out in kidney biopsies from patients with chronic kidney disease (CKD). Experimental data indicated that this decrease was a strong determinant of renal fibrogenesis, hence a focus for therapeutic interventions. Nevertheless, whether persistently differentiated renal tubules, surviving in a pro-fibrotic environment, also suffer from a decrease in FAO, is currently unknown. METHODS To address this question, we isolated proximal tubules captured ex vivo on the basis of the expression of an intact brush border antigen (Prominin-1) in C57BL6/J mice subjected to a controlled, two-hit model of renal fibrosis (reversible ischemic acute kidney injury (AKI) or sham surgery, followed by angiotensin 2 administration). A transcriptomic high throughput sequencing was performed on total mRNA from these cells, and on whole kidneys. RESULTS In contrast to mice subjected to sham surgery, mice with a history of AKI displayed histologically more renal fibrosis when exposed to angiotensin 2. High throughput RNA sequencing, principal component analysis and clustering showed marked consistency within experimental groups. As expected, FAO transcripts were decreased in whole fibrotic kidneys. Surprisingly, however, up- rather than down-regulation of metabolic pathways (oxidative phosphorylation, fatty acid metabolism, glycolysis, and PPAR signalling pathway) was a hallmark of the differentiated tubules captured from fibrotic kidneys. Immunofluorescence co-staining analysis confirmed that the expression of FAO enzymes was dependent of tubular trophicity. CONCLUSIONS These data suggest that in differentiated proximal tubules energetic hyperactivity is promoted concurrently with organ fibrogenesis.
Collapse
Affiliation(s)
- Aurélien Bataille
- Sorbonne Universités, INSERM UMR S 1155, Hôpital Tenon, Paris, France.,Department of Anesthesiology and Critical Care Medicine, Lariboisiere Hospital, University Paris 7 Diderot, U942, Inserm, Paris, France
| | - Pierre Galichon
- Sorbonne Universités, INSERM UMR S 1155, Hôpital Tenon, Paris, France
| | - Nadjim Chelghoum
- APHP, Hôpital Tenon, Urgences Néphrologiques et Transplantation Rénale, 4 rue de la Chine, Paris, France
| | | | | | - Iman Sadia
- Sorbonne Universités, INSERM UMR S 1155, Hôpital Tenon, Paris, France
| | | | | | - David Legouis
- Sorbonne Universités, INSERM UMR S 1155, Hôpital Tenon, Paris, France
| | - Raphaël Cohen
- Sorbonne Universités, INSERM UMR S 1155, Hôpital Tenon, Paris, France
| | - Yi-Chun Xu-Dubois
- Sorbonne Universités, INSERM UMR S 1155, Hôpital Tenon, Paris, France
| | - Morgane Commereuc
- Sorbonne Universités, INSERM UMR S 1155, Hôpital Tenon, Paris, France
| | - Eric Rondeau
- Sorbonne Universités, INSERM UMR S 1155, Hôpital Tenon, Paris, France.,APHP, Hôpital Tenon, Urgences Néphrologiques et Transplantation Rénale, 4 rue de la Chine, Paris, France
| | - Stéphane Le Crom
- Sorbonne Universités, UPMC Université Paris 06, CNRS, Institut de Biologie Paris-Seine (IBPS), Evolution Paris Seine, Paris, France
| | - Alexandre Hertig
- Sorbonne Universités, INSERM UMR S 1155, Hôpital Tenon, Paris, France
| |
Collapse
|
6
|
Matignon M, Pilon C, Commereuc M, Grondin C, Leibler C, Kofman T, Audard V, Cohen J, Canoui-Poitrine F, Grimbert P. Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study. PLoS One 2017; 12:e0178572. [PMID: 28654684 PMCID: PMC5487035 DOI: 10.1371/journal.pone.0178572] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Accepted: 05/15/2017] [Indexed: 02/07/2023] Open
Abstract
Background Approximately 25% of kidney transplant recipients develop de novo anti-HLA donor-specific antibodies (dnDSA) leading to acute antibody-mediated rejection (ABMR) in 30% of patients. Preemptive therapeutic strategies are not available. Methods We conducted a prospective observational study including 11 kidney transplant recipients. Inclusion criteria were dnDSA occurring within the first year after transplant and normal allograft biopsy. All patients were treated with high-dose IVIG (2 g/kg 0, 1 and 2 months post-dnDSA). The primary efficacy outcome was incidence of clinical and subclinical acute ABMR within 12 months after dnDSA detection as compared to a historical control group (IVIG-). Results Acute ABMR occurred in 2 or 11 patients in the IVIG+ group and in 1 of 9 patients in the IVIG- group. IVIG treatment did not affect either class I or class II DSA, as observed at the end of the follow-up. IVIG treatment significantly decreased FcγRIIA mRNA expression in circulating leukocytes, but did not affect the expression of any other markers of B cell activation. Conclusions In this first pilot study including kidney allograft recipients with early dnDSA, preemptive treatment with high-dose IVIG alone did not prevent acute ABMR and had minimal effects on DSA outcome and B cell phenotype.
Collapse
Affiliation(s)
- Marie Matignon
- AP-HP, Henri Mondor Hospital, Nephrology and Transplantation Department and CIC Biothérapies 504, Créteil, France
- INSERM U955, Team 21, Créteil, France and Paris Est University (UPEC), Créteil, France
- * E-mail:
| | - Caroline Pilon
- INSERM U955, Team 21, Créteil, France and Paris Est University (UPEC), Créteil, France
- AP-HP, Henri Mondor Hospital, CIC Biothérapies 504, Créteil France
| | - Morgane Commereuc
- AP-HP, Henri Mondor Hospital, Nephrology and Transplantation Department, Créteil, France
| | - Cynthia Grondin
- AP-HP, Henri Mondor Hospital, CIC Biothérapies 504, Créteil France
- INSERM U955, Team 21, Créteil, France
| | - Claire Leibler
- INSERM U955, Team 21, Créteil, France and Paris Est University (UPEC), Créteil, France
- AP-HP, Henri Mondor Hospital, Nephrology and Transplantation Department, Créteil, France
| | - Tomek Kofman
- AP-HP, Henri Mondor Hospital, Nephrology and Transplantation Department, Créteil, France
| | - Vincent Audard
- INSERM U955, Team 21, Créteil, France and Paris Est University (UPEC), Créteil, France
- AP-HP, Henri Mondor Hospital, Nephrology and Transplantation Department, Créteil, France
| | - José Cohen
- INSERM U955, Team 21, Créteil, France and Paris Est University (UPEC), Créteil, France
- AP-HP, Henri Mondor Hospital, CIC Biothérapies 504, Créteil France
| | - Florence Canoui-Poitrine
- AP-HP, Henri-Mondor Hospital, Public Health Department, Creteil, France
- Paris-Est University, UPEC, IMRB-EA 7376 CEpiA unit (Clinical Epidemiology And Ageing), Creteil, France
| | - Philippe Grimbert
- AP-HP, Henri Mondor Hospital, Nephrology and Transplantation Department and CIC Biothérapies 504, Créteil, France
- INSERM U955, Team 21, Créteil, France and Paris Est University (UPEC), Créteil, France
| |
Collapse
|
7
|
Commereuc M, Weill FX, Loukiadis E, Gouali M, Gleizal A, Kormann R, Ridel C, Frémeaux-Bacchi V, Rondeau E, Hertig A. Recurrent Hemolytic and Uremic Syndrome Induced by Escherichia Coli. Medicine (Baltimore) 2016; 95:e2050. [PMID: 26735524 PMCID: PMC4706244 DOI: 10.1097/md.0000000000002050] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
A widespread belief is that typical hemolytic and uremic syndrome (HUS) does not recur. We report the case of a patient infected twice with raw milk taken from his own cow and containing a Shiga toxin-producing Escherichia coli O174:H21 that induced recurrent HUS causing severe renal and cerebral disorders. A genomic comparison of the human and bovine Shiga toxin-producing Escherichia coli O174:H21 isolates revealed that they were identical. Typical HUS may recur. Since milk from this animal was occasionally distributed locally, thereby posing a serious threat for the whole village, this particular cow was destroyed.
Collapse
Affiliation(s)
- Morgane Commereuc
- From the APHP, Hôpital Tenon (MC, RK, CR, ER, AH), Urgences Néphrologiques et Transplantation Rénale, Institut Pasteur (F-XW, MG), Unité des Bactéries Pathogènes Entériques, Centre National de Référence des E coli et Shigella, Paris, VetAgro Sup (EL, AG), Campus vétérinaire de Lyon, Laboratoire d'études des microorganismes alimentaires pathogènes (LMAP), Laboratoire National de Référence pour les E coli y compris les E coli producteurs de Shiga-toxines (LNR STEC), Marcy L'Etoile, Service d'Immunologie, Hôpital Européen Georges Pompidou (VF-B); and UPMC Sorbonne Université Paris 06 (ER, AH), Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Commereuc M, Rondeau E, Ridel C. [Acute kidney injury in elderly patient: Diagnostic and therapeutic aspects]. Presse Med 2014; 43:341-7. [PMID: 24560978 DOI: 10.1016/j.lpm.2013.07.030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Revised: 06/08/2013] [Accepted: 07/08/2013] [Indexed: 10/25/2022] Open
Abstract
Acute renal failure in elderly patient is a public health problem. It is worsen by physiological status and anatomical changes associated with age, polymedication and chronic diseases. The etiologies of acute renal failure in the elderly are the same as in adults. Their distribution is specific with a large proportion of obstructive acute renal failure. The diagnostic and therapeutic strategies are the same as for young adults; the injection of iodinated-contrast should be avoided. Therapeutic strategies are discussed in terms of quality of life pre-morbid. Age is not considered a determinant of intensive treatment decisions. Renal replacement therapy in the elderly is not associated with excess mortality. Prevention of acute renal failure should be a permanent concern.
Collapse
Affiliation(s)
- Morgane Commereuc
- Hôpital Tenon, service d'urgences néphrologiques et transplantation rénale, 75020 Paris, France.
| | - Eric Rondeau
- Hôpital Tenon, service d'urgences néphrologiques et transplantation rénale, 75020 Paris, France
| | - Christophe Ridel
- Hôpital Tenon, service d'urgences néphrologiques et transplantation rénale, 75020 Paris, France
| |
Collapse
|
9
|
Commereuc M, Contou D, Thille AW, Brun-Buisson C. Incidence of shoulder injuries after generalized tonic-clonic seizure admitted to intensive care. Seizure 2013; 23:84-5. [PMID: 23948122 DOI: 10.1016/j.seizure.2013.07.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2013] [Revised: 07/22/2013] [Accepted: 07/24/2013] [Indexed: 11/15/2022] Open
Affiliation(s)
- Morgane Commereuc
- Medical Intensive Care Unit, AP-HP, Albert Chenevier - Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France.
| | - Damien Contou
- Medical Intensive Care Unit, AP-HP, Albert Chenevier - Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France.
| | - Arnaud W Thille
- Medical Intensive Care Unit, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers, France.
| | - Christian Brun-Buisson
- Medical Intensive Care Unit, AP-HP, Albert Chenevier - Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France.
| |
Collapse
|